TABLE 3.
Subgroup analysis of Infarct size.
| Subgroup | No.of studies | SMD | 95%CI | p-Value between subgroups | Heterogeneity within subgroups | |
|---|---|---|---|---|---|---|
| I2 (%) | p-Value | |||||
| Model | 0.12 | |||||
| Block LAD | 9 | −2.79 | −3.80, −1.78 | 66% | <0.01 | |
| Ligation and reperfusion | 9 | −5.72 | −9.25, −2.18 | 91% | <0.01 | |
| Dosage | <0.01 | |||||
| ≤20 mg/kg | 6 | −1.55 | −2.08, −1.03 | 0% | 0.46 | |
| 21–50 mg/kg | 5 | −4.84 | −7.19, −2.49 | 80% | <0.01 | |
| >50 mg/kg | 7 | −6.12 | −10.51, −1.73 | 89% | <0.01 | |
| Administration method | 0.29 | |||||
| Intravenous injection | 11 | −2.9 | −3.76, −2.03 | 66% | <0.01 | |
| gavage | 3 | −4.43 | −7.40, −1.46 | 84% | <0.01 | |
| intraperitoneal injection | 4 | −8.45 | −16.96, 0.05 | 96% | <0.01 | |
| Administration time | 0.34 | |||||
| before modeling | 7 | −6.42 | −11.10, −1.74 | 93% | <0.01 | |
| after modeling | 7 | −2.83 | −4.09, −1.57 | 73% | <0.01 | |
| other times | 4 | −3.26 | −4.79, −1.72 | 62% | 0.05 | |
| Species | 0.11 | |||||
| SD rats | 15 | −4.66 | −6.74, −2.58 | 87% | <0.01 | |
| Wistar rats | 2 | −3.01 | −4.49, −1.54 | 55% | 0.13 | |
| 4-way ovoss | 1 | −1.86 | −3.48, −0.25 | - | - | |